针对 IgA 肾病,荣昌生物“泰它西普”拟优先审评

抗体圈
Sep 28

▲体内CAR疗法-全球研究与发展格局(2025)免费领取!9 月 28 日,CDE 官网显示,荣昌生物泰它西普拟纳入优先审评品种,用于治疗具有进展风险的原发性免疫球蛋白 A(IgA)肾病成人患者,显著降低蛋白尿水平。来源:CDE 官网此前 8 月 27 日,荣昌生物宣布泰它西普治疗 lgA 肾病的国内 III 期研究达成 A 阶段的主要终点。研究结果显示,与安慰剂组相比,泰它西普组患者在治疗 39...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10